IP Library › Patent Application 19348319
Patent Application
App. No. 19/348,319

FRB ANTIBODIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/348,319
Abstract

The invention provides anti-FRB antibodies or antigen binding fragments thereof.

Claims (25)

1 . An anti-FKBP Rapamycin binding (FRB) antibody that binds an FRB polypeptide, wherein the antibody comprises two light chains and two heavy chains,

wherein each light chain comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in any one of SEQ ID NOs: 1-3, 11-13, 21-23, 31-33, and 41-43, and

wherein each heavy chain comprises a heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in any one of SEQ ID NOs: 4-6, 14-16, 24-26, 34-36, and 44-46, respectively.

2 . The anti-FRB antibody of claim 1 , wherein the light chain variable region of each light chain comprises the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 1-3, and wherein the heavy chain variable region of each heavy chain comprises the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 4-6.

3 . The anti-FRB antibody of claim 1 , wherein the light chain variable region of each light chain comprises the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 11-13, and wherein the heavy chain variable region of each heavy chain comprises the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 14-16.

4 . The anti-FRB antibody of claim 1 , wherein the light chain variable region of each light chain comprises the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 21-23, and wherein the heavy chain variable region of each heavy chain comprises the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 24-26.

5 . The anti-FRB antibody of claim 1 , wherein the light chain variable region of each light chain comprises the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 31-33, and wherein the heavy chain variable region of each heavy chain comprises the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 34-36.

6 . The anti-FRB antibody of claim 1 , wherein the light chain variable region of each light chain comprises the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 41-43, and wherein the heavy chain variable region of each heavy chain comprises the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 44-46.

7 . The anti-FRB antibody of claim 1 , wherein each light chain variable region comprises a variable light chain sequence as set forth in any one of SEQ ID NOs: 7, 9, 17, 19, 27, 29, 37, 39, 47, and 49, and wherein each heavy chain variable region comprises a variable heavy chain sequence as set forth in any one of SEQ ID NOs: 8, 10, 18, 20, 28, 30, 38, 40, 48, and 50, respectively.

8 . The anti-FRB antibody of claim 1 , wherein each light chain variable region comprises a variable light chain sequence as set forth in SEQ ID NO: 7 or SEQ ID NO: 9, and wherein each heavy chain variable region comprises a variable heavy chain sequence as set forth in SEQ ID NO: 8 or SEQ ID NO: 10.

9 . The anti-FRB antibody of claim 1 , wherein each light chain variable region comprises a variable light chain sequence as set forth in SEQ ID NO: 17 or SEQ ID NO: 19, and wherein each heavy chain variable region comprises a variable heavy chain sequence as set forth in SEQ ID NO: 18 or SEQ ID NO: 20.

10 . The anti-FRB antibody of claim 1 , wherein each light chain variable region comprises a variable light chain sequence as set forth in SEQ ID NO: 27 or SEQ ID NO: 29, and wherein each heavy chain variable region comprises a variable heavy chain sequence as set forth in SEQ ID NO: 28 or SEQ ID NO: 30.

11 . The anti-FRB antibody of claim 1 , wherein each light chain variable region comprises a variable light chain sequence as set forth in SEQ ID NO: 37 or SEQ ID NO: 39, and wherein each heavy chain variable region comprises a variable heavy chain sequence as set forth in SEQ ID NO: 38 or SEQ ID NO: 40.

12 . The anti-FRB antibody of claim 1 , wherein each light chain variable region comprises a variable light chain sequence as set forth in SEQ ID NO: 47 or SEQ ID NO: 49, and wherein each heavy chain variable region comprises a variable heavy chain sequence as set forth in SEQ ID NO: 48 or SEQ ID NO: 50.

13 .- 14 . (canceled)

15 . The anti-FRB antibody of claim 1 , wherein the antibody is a monoclonal antibody.

16 . (canceled)

17 . The anti-FRB antibody of claim 1 , wherein the antibody binds an FRB polypeptide sequence set forth in SEQ ID NO: 51.

18 . A conjugate, comprising the anti-FRB antibody of claim 1 and a detectable label.

19 . The conjugate of claim 18 , wherein the detectable label is selected from the group consisting of: a hapten, a fluorescent dye, a fluorescent protein, a chromophore, a metal ion, a gold particle, a silver particle, a magnetic particle, a polypeptide, an enzyme, a luminescent compound, or an oligonucleotide.

20 . A polynucleotide encoding the anti-FRB antibody of claim 1 .

21 . A composition comprising the anti-FRB antibody of claim 1 .

22 . A hybridoma comprising (i) the anti-FRB antibody of claim 1 , or (ii) one or more polynucleotides encoding the anti-FRB antibody of claim 1 .

23 . (canceled)

24 . A composition comprising the polynucleotide of claim 20 .